Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Exelixis
National Institutes of Health Clinical Center (CC)
University of California, Irvine
Pediatric Brain Tumor Consortium
European Organisation for Research and Treatment of Cancer - EORTC
City of Hope Medical Center
University of Alabama at Birmingham
Day One Biopharmaceuticals, Inc.
Alaunos Therapeutics
BioMimetix JV, LLC
Massachusetts General Hospital
University of Oklahoma
Thomas Jefferson University
Bayer
BeiGene
Children's Oncology Group
National Cancer Institute (NCI)
Grupo Español de Investigación en Neurooncología
Washington University School of Medicine
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Radiation Therapy Oncology Group
University of California, San Francisco
Istari Oncology, Inc.
Memorial Sloan Kettering Cancer Center
Candel Therapeutics, Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Novartis
University of Nebraska
National Institutes of Health Clinical Center (CC)
Sumitomo Pharma America, Inc.
European Organisation for Research and Treatment of Cancer - EORTC
National Institutes of Health Clinical Center (CC)
City of Hope Medical Center
TVAX Biomedical
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
The University of Texas Health Science Center at San Antonio
TVAX Biomedical
Rush University Medical Center
Children's Oncology Group
Karyopharm Therapeutics Inc
Northwestern University
University of California, San Francisco
Indiana University
M.D. Anderson Cancer Center
Weill Medical College of Cornell University
Burzynski Research Institute
Emory University
National Cancer Institute (NCI)